Last reviewed: July 14, 2026 Last updated: July 14, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Ozempic is approved for the management of type-2 diabetes
Timing can shift based on your individual biology
However, it is currently unknown whether ALA can affect sE through the JAK2/STAT3 pathway
We can also trend key labs to provide more objective evidence of improved health
Under the MFN framework, Medicare and Medicaid programs are expected to access select GLP-1s at approximately $245 per month, though coverage for weight-loss-only use remains limited or excluded in many states